Product Code: 35696
Polio Vaccine Market Size And Forecast
Polio Vaccine Market size is valued at USD 699.5 Million in the year 2024 and is projected to reach USD 1067.81 Million in 2032, growing at a CAGR of 4.6% from 2026 to 2032.
Global Polio Vaccine Market Drivers
The market drivers for the Polio Vaccine Market can be influenced by various factors. These may include:
- Government Initiatives and Vaccination Programmes: In an effort to end polio, numerous nations have started massive vaccination campaigns in cooperation with international agencies like UNICEF and the World Health Organisation (WHO). The need for polio vaccines is greatly fueled by these initiatives.
- Growing Polio Incidence in Some Areas: In spite of international efforts, polio outbreaks continue to happen, especially in some areas of Asia and Africa. Vaccination efforts are stepped up in response to these outbreaks in an attempt to contain and stop the disease's spread.
- Technological Developments in Vaccines: New developments in vaccine technology, such as the creation of safer and more effective vaccinations, support market expansion. Novel delivery methods and improved vaccine formulations are examples of advances that increase immunisation uptake and efficacy.
- Growing Knowledge and Healthcare Spending: The market is supported by growing knowledge of the value of vaccinations as well as growing healthcare spending in many nations. The demand for vaccines is rising as governments and non-governmental organisations invest more in healthcare facilities and immunisation programmes.
- Global Polio Eradication Initiatives: By providing money and assistance for vaccination programmes worldwide, organisations such as the Global Polio Eradication Initiative (GPEI) are crucial in propelling the market. Their work is essential to keeping a high immunisation rate and tracking polio outbreaks.
- Rising Birth Rates in Developing Nations: A greater target population for polio vaccination is produced by rising birth rates in developing nations. The ongoing need for polio immunisations is influenced by this demographic aspect.
- Partnerships and Collaborations: Governments, non-governmental organisations (NGOs), and businesses in the private sector work together to improve the efficacy and reach of polio vaccine campaigns, which propels market expansion.
- Economic Gains from Polio Eradication: Governments and organisations are encouraged to invest in vaccination programmes by the financial gains from polio eradication, which include lower healthcare expenses and increased productivity. This increases demand in the market.
- Regulatory Support and Approvals: The expansion of the industry is facilitated by favourable regulatory frameworks and expedited FDA and EMA approvals for novel vaccines. The timely distribution and availability of vaccines is guaranteed by regulatory support.
Global Polio Vaccine Market Restraints
Several factors can act as restraints or challenges for the Polio Vaccine Market . These may include:
- Manufacturing Difficulties: Strict quality control and biosafety procedures are needed during the production of polio vaccines. Shortages of supplies can result from any interference with the manufacturing process, including contamination and equipment malfunctions.
- Cold Chain Logistics: To preserve their effectiveness, polio vaccines, especially the oral polio vaccine (OPV), must be transported and stored at a certain temperature. Inadequate cold chain facilities can make it more difficult to distribute vaccines, particularly in low-income areas.
- Financial Restraints: Governments and international organisations are frequently the source of funding for polio immunisation campaigns. The extent of immunisation efforts and the availability of vaccinations may be restricted by a lack of financing.
- Cost of Vaccination Programmes: The expenses associated with putting in place extensive vaccination programmes, such as those related to staffing, logistics, and public awareness campaigns, can add up. The frequency and reach of vaccination drives might be impacted by financial limitations.
- Political Instability: Because of population dislocation and security concerns, areas undergoing political unrest or violence may find it challenging to implement regular and extensive vaccination campaigns.
- Vaccine hesitation: In communities, vaccine hesitation can be caused by misinformation and mistrust of vaccinations. Misconceptions and cultural beliefs regarding the effectiveness and safety of vaccinations can lower vaccination rates.
- Regulatory Approvals: Getting regulatory permission for brand-new vaccines or modifications to already-approved ones may be a difficult and drawn-out procedure, which may cause a delay in the product's release onto the market.
- Policy Variations: Health policies and regulatory frameworks differ among nations, which might make it more difficult for polio vaccinations to be distributed and accepted internationally.
- Emerging Health Crises: Polio vaccination campaigns may receive less attention and funding as a result of outbreaks of other diseases like COVID-19. Health systems can give priority to current risks over ongoing efforts to eradicate polio.
- Vaccine Development: It can be expensive and technically difficult to create new and improved polio vaccines, such as those that offer easier administration or longer-lasting immunity.
- Innovation Stagnation: The market's ability to grow may be hampered by a lack of innovation in vaccination technology as a result of high costs and risk issues.
- Challenges associated with near-eradication: As polio is almost completely eradicated, people may become less inclined to get vaccinated, which could result in a decline in vaccination rates. There is a chance that this will resurface.
Global Polio Vaccine Market Segmentation Analysis
The Global Polio Vaccine Market is Segmented on the basis of Polio Vaccine Type, Application, and Geography.
Polio Vaccine Market, By Polio Vaccine Type
- Oral Polio Vaccine (OPV)
- Inactivated Poliomyelitis Vaccine (IPV)
- Based on Polio Vaccine Type, the market is bifurcated into, Oral Polio Vaccine (OPV), Inactivated Poliomyelitis Vaccine (IPV). OralPolio Vaccine is leading in the segment used in the fight to eradicate polio and it can replicate effectively in the intestine which enables an individual to mount an immune response against the virus
Polio Vaccine Market, By Application
- Public
- Private
- Based on Application, the market is bifurcated into the public and private segments. The public segment is estimated to hold the largest share. Government policies and their fight to eradicate polio has been the major cause for the growth of the segment
Polio Vaccine Market, By Geography
- North America
- Europe
- Asia Pacific
- Rest of the world
- On the basis of Geography, the Global Polio Vaccine Market is classified into North America, Europe, Asia Pacific, and the Rest of the world. Asia Pacific region is leading in the segment and holds the largest industry in the globe, as the number of polio vaccination is highest in the region. North America and Europe also hold a decent amount of share in the market
Key Players
- The major players in the Polio Vaccine Market are:
- Pfizer
- Sanofi, Astellas Pharma
- Serum Institute of India Pvt. Ltd.
- Haffkine Bio-Pharmaceutical Corporation Ltd.
- Panacea Biotec Ltd.
- GlaxoSmithKline (UK)
- Bharat Biotech (India)
- China National Biotec Group (China)
- Walvax Biotechnology Co., Ltd. (China)
- IMVAM (Canada)
TABLE OF CONTENTS
1 INTRODUCTION OF GLOBAL POLIO VACCINE MARKET
- 1.1 Overview of the Market
- 1.2 Scope of Report
- 1.3 Assumptions
2 EXECUTIVE SUMMARY
3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH
- 3.1 Data Mining
- 3.2 Validation
- 3.3 Primary Interviews
- 3.4 List of Data Sources
4 GLOBAL POLIO VACCINE MARKET OUTLOOK
- 4.1 Overview
- 4.2 Market Dynamics
- 4.2.1 Drivers
- 4.2.2 Restraints
- 4.2.3 Opportunities
- 4.3 Porters Five Force Model
- 4.4 Value Chain Analysis
5 GLOBAL POLIO VACCINE MARKET, BY POLIO VACCINE TYPE
- 5.1 Overview
- 5.2 Oral Polio Vaccine (OPV)
- 5.3 Inactivated Poliomyelitis Vaccine (IPV)
6 GLOBAL POLIO VACCINE MARKET, BY APPLICATION
- 6.1 Overview
- 6.2 Public
- 6.3 Private
7 GLOBAL POLIO VACCINE MARKET, BY GEOGRAPHY
- 7.1 Overview
- 7.2 North America
- 7.2.1 U.S.
- 7.2.2 Canada
- 7.2.3 Mexico
- 7.3 Europe
- 7.3.1 Germany
- 7.3.2 U.K.
- 7.3.3 France
- 7.3.4 Rest of Europe
- 7.4 Asia Pacific
- 7.4.1 China
- 7.4.2 Japan
- 7.4.3 India
- 7.4.4 Rest of Asia Pacific
- 7.5 Rest of the World
- 7.5.1 Latin America
- 7.5.2 Middle East And Africa
8 GLOBAL POLIO VACCINE MARKET COMPETITIVE LANDSCAPE
- 8.1 Overview
- 8.2 Company Market Ranking
- 8.3 Key Development Strategies
9 COMPANY PROFILES
- 9.1 Pfizer
- 9.1.1 Overview
- 9.1.2 Financial Performance
- 9.1.3 Product Outlook
- 9.1.4 Key Developments
- 9.2 GlaxoSmithKline
- 9.2.1 Overview
- 9.2.2 Financial Performance
- 9.2.3 Product Outlook
- 9.2.4 Key Developments
- 9.3 Sanofi
- 9.3.1 Overview
- 9.3.2 Financial Performance
- 9.3.3 Product Outlook
- 9.3.4 Key Developments
- 9.4 Astellas Pharma
- 9.4.1 Overview
- 9.4.2 Financial Performance
- 9.4.3 Product Outlook
- 9.4.4 Key Developments
- 9.5 Serum Institute of India Pvt. Ltd.
- 9.5.1 Overview
- 9.5.2 Financial Performance
- 9.5.3 Product Outlook
- 9.5.4 Key Developments
- 9.6 Haffkine Bio-Pharmaceutical Corporation Ltd.
- 9.6.1 Overview
- 9.6.2 Financial Performance
- 9.6.3 Product Outlook
- 9.6.4 Key Developments
- 9.7 Panacea Biotec Ltd
- 9.7.1 Overview
- 9.7.2 Financial Performance
- 9.7.3 Product Outlook
- 9.7.4 Key Developments
10 Appendix